A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Status:
Completed
Trial end date:
2021-09-03
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the
safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of
etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in
participants with advanced malignancies.